BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11604553)

  • 1. Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.
    Schellens JH; Planting AS; Ma J; Maliepaard M; de Vos A; de Boer Dennert M; Verweij J
    Anticancer Drugs; 2001 Sep; 12(8):667-75. PubMed ID: 11604553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
    Schellens JH; Planting AS; van Zandwijk N; Ma J; Maliepaard M; van der Burg ME; de Boer-Dennert M; Brouwer E; van der Gaast A; van den Bent MJ; Verweij J
    Br J Cancer; 2003 Mar; 88(6):814-21. PubMed ID: 12644815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
    Planting AS; de Mulder PH; de Graeff A; Verweij J
    Eur J Cancer; 1997 Jan; 33(1):61-5. PubMed ID: 9071901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
    Planting AS; Catimel G; de Mulder PH; de Graeff A; Höppener F; Verweij J; Oster W; Vermorken JB
    Ann Oncol; 1999 Jun; 10(6):693-700. PubMed ID: 10442192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
    Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism.
    Weisman RA; Christen R; Los G; Jones V; Kerber C; Seagren S; Glassmeyer S; Orloff LA; Wong W; Kirmani S; Howell S
    Otolaryngol Head Neck Surg; 1998 May; 118(5):597-602. PubMed ID: 9591856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
    Schellens JH; Ma J; Planting AS; van der Burg ME; van Meerten E; de Boer-Dennert M; Schmitz PI; Stoter G; Verweij J
    Br J Cancer; 1996 Jun; 73(12):1569-75. PubMed ID: 8664132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer.
    Espeli V; Zucca E; Ghielmini M; Giannini O; Salatino A; Martucci F; Richetti A
    Oral Oncol; 2012 Mar; 48(3):266-71. PubMed ID: 22079100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In squamous cell head and neck cancer: which platinum, how much and how often?
    Nwizu T; Adelstein DJ
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):1033-9. PubMed ID: 24998393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
    Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
    Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
    Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
    Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
    Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.